We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

167 hedge funds and large institutions have $1.41B invested in Coherus Oncology in 2019 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 56 increasing their positions, 43 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more call options, than puts

Call options by funds: $15.8M | Put options by funds: $4.99M

115% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 20

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

30% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 43

14% more funds holding

Funds holding: 146 → 167 (+21)

3.11% more ownership

Funds ownership: 96.32% → 99.43% (+3.1%)

5% less capital invested

Capital invested by funds: $1.47B → $1.41B (-$67.9M)

Holders
167
Holders Change
+21
Holders Change %
+14.38%
% of All Funds
3.66%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
43
Increased
56
Reduced
43
Closed
20
Calls
$15.8M
Puts
$4.99M
Net Calls
+$10.8M
Net Calls Change
+$3.31M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$26.7M
2
RHJA
Rice Hall James & Associates
California
+$14.1M
3
N
Nuveen
North Carolina
+$13.3M
4
Ameriprise
Ameriprise
Minnesota
+$9.96M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$9.81M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$15.3M
2
JP Morgan Chase
JP Morgan Chase
New York
-$11.8M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$9.99M
4
HP
Hound Partners
New York
-$9.47M
5
DCM
Driehaus Capital Management
Illinois
-$9.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
AM
126
Ares Management
California
$232K – – –
Jane Street
127
Jane Street
New York
$222K -$165K -8,239 -43%
Principal Financial Group
128
Principal Financial Group
Iowa
$219K +$3.54K +177 +2%
Balyasny Asset Management
129
Balyasny Asset Management
Illinois
$214K -$4.33M -216,635 -95%
XK
130
Xact Kapitalforvaltning
Sweden
$207K – – –
RBFC
131
Roman Butler Fullerton & Co
Missouri
$203K +$200K +10,000 New
Victory Capital Management
132
Victory Capital Management
Texas
$200K +$197K +9,863 New
BNP Paribas Financial Markets
133
BNP Paribas Financial Markets
France
$195K +$76.1K +3,810 +66%
PIM
134
Partner Investment Management
California
$158K -$95.9K -4,801 -38%
Bank of Montreal
135
Bank of Montreal
Ontario, Canada
$110K +$5.5K +275 +5%
AG
136
Advisor Group
Arizona
$108K +$106K +5,323 New
AIP
137
Ameritas Investment Partners
Nebraska
$107K – – –
TAM
138
Tiverton Asset Management
Delaware
$90K – – –
Zurich Cantonal Bank
139
Zurich Cantonal Bank
Switzerland
$73K – – –
First Manhattan
140
First Manhattan
New York
$70K +$69.9K +3,500 New
EP
141
Elkfork Partners
Oregon
$56K – – –
TRCT
142
Tower Research Capital (TRC)
New York
$52K +$50.8K +2,545 New
GHCM
143
Glen Harbor Capital Management
California
$46K – – –
PCG
144
Private Capital Group
Connecticut
$40K +$39.2K +1,964 New
MCIM
145
Meadow Creek Investment Management
Georgia
$36K – – –
SLF
146
Sun Life Financial
Ontario, Canada
$35K +$34.7K +1,735 New
CG
147
Cutler Group
California
$32K +$32K +1,600 New
FCM
148
Flinton Capital Management
Pennsylvania
$26K – – –
IUHSA
149
Itau Unibanco Holding S.A.
Brazil
$22K – – –
EIP
150
Ellis Investment Partners
Pennsylvania
$19K – – –
4 5
6
7 8

CHRS Hedge Fund Activity: Q3 2019 in Review

167 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2019, worth a combined $1.41B — down 4.6% from $1.47B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new CHRS positions and 20 closed out — a net gain of 23 holders — while 56 added to existing stakes and 43 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $26.7M. The largest seller was PFM Health Sciences, cutting an estimated $15.3M.

  • 167 institutional investors held Coherus Oncology (CHRS) as of Q3 2019, up from 146 in Q2 2019.
  • Funds reported $1.41B of Coherus Oncology stock for Q3 2019, down 4.6% quarter-over-quarter.
  • 43 funds opened new Coherus Oncology positions in Q3 2019 and 20 closed out, a net change of +23 holders.
  • The largest Coherus Oncology buyer in Q3 2019 was Rubric Capital Management (New York), an estimated $26.7M added.
  • The largest Coherus Oncology seller in Q3 2019 was PFM Health Sciences, an estimated $15.3M sold.

Based on aggregated 13F filings for Q3 2019.